ClinicalTrials.gg
CompletedNCT03382262Updated Jan 24, 2024Results posted

Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

A Phase 2 interventional study of FX006 32 mg and TAcs 40 mg in Osteoarthritis of the Shoulder and Osteoarthritis of the Hip, sponsored by Pacira Pharmaceuticals, Inc. Completed at 6 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-01-24.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 155 studies in Osteoarthritis, Hip with a site in United States — 21 open to participants now, 32 under way, 1 of them phase 3. Osteoarthritis, Hip · United States.

Enrollment
85th of 118
55 · median 105
Started
2017
with 9 others
Phase 2
10 of 155
1 open now
Registered
72nd of 155
by date
Lead sponsor
4 of 155
Pacira Pharmaceuticals, Inc

Among the 155 studies in Osteoarthritis, Hip with a site in United States, this one is the 85th largest by enrollment of the 118 interventional ones that give a count, is one of 10 that started in 2017, is one of 10 in phase 2, and was the 72nd registered.

Osteoarthritis, Hip

642 studies on the registry are indexed under Osteoarthritis, Hip; 121 are open to participants now.

Browse Osteoarthritis, Hip studies →

Open to participants now

21 of the 155 studies in Osteoarthritis, Hip with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Osteoarthritis, Hip studies recruiting now, 54 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Osteoarthritis, Hip with a site in United States, or all of them as a file.
02

Study summary

This is an open-label study to compare systemic exposure to triamcinolone acetonide following a dose of extended-release FX006 or immediate-release TAcs (triamcinolone acetonide suspension) in patients with osteoarthritis of the shoulder (glenohumeral joint) or hip

Read the detailed description

This is a randomized, open-label, single dose study that will be conducted in male and female patients ≥40 years of age with OA of either the shoulder or the hip.

Approximately 24 patients with OA of the shoulder and approximately 24 patients with OA of the hip will be randomized to one of two treatment groups (1:1) and treated with a single IA injection of either:

  • 32 mg FX006 (approximately 12 patients per joint) or
  • 40 mg TAcs (approximately 12 patients per joint)

Each patient will be screened to confirm the diagnosis of OA of either the shoulder or hip and eligibility based on the other inclusion/exclusion requirements and will be randomized to treatment on Day 1. Each patient will be evaluated for a total of 12 weeks following the IA injection. Following screening, sampling for pharmacokinetics (PK) and safety will be completed at 10 out-patient visits scheduled on Study Days 1 [calendar day of injection], 2, 3, 5, 8, 15, 22, 29, 57, and 85.

03

Conditions studied

  • Osteoarthritis of the Shoulder
  • Osteoarthritis of the Hip

Keywords

  • Osteoarthritis
  • Shoulder
  • Hip
  • Pain
  • Intra-articular
  • Injection
  • Corticosteroid
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written consent to participate in the study
  • Male or female greater than or equal to 40 years of age
  • (BMI) less than or equal to 40 kg/m2
  • Ambulatory and in good general health
  • Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions
  • Willing to abstain from use of protocol-restricted treatments from Screening through End-of-Study visit
  • Symptoms consistent with OA of the index joint for ≥ 6 months prior to Screening (patient reported is acceptable)
  • Pain in the index joint for greater than15 days over the last month (as reported by the patient)
  • For Shoulder OA patients: Radiologic findings of OA of the index shoulder meeting the Samilson-Prieto (S-P) Classification Grades 2 or 3
  • For Hip OA patients: ACR Criteria (clinical and radiological) for OA of the index hip

Exclusion criteria

Exclusion Criteria:

  • Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease
  • History of infection in the index joint
  • Clinical findings consistent with active infection or crystal disease in the index joint within 1 month of Screening
  • History of fracture in the index limb within 12 months of Screening, or fracture with sequelae at any time
  • Planned or anticipated surgery of the index joint during the study period
  • Index joint instability or history of acute dislocation within 12 months of Screening
  • If shoulder is the index joint, history of full or partial rotator cuff tear or significantly compromised rotator cuff function that, in the opinion for the Investigator, increases the difficulty or risk of IA injection
  • Presence of surgical hardware or other foreign body in the index joint
  • Surgery or arthroscopy of the index joint within 12 months of Screening
  • IA treatment of any joint with any of the following agents within 6 months of Screening:
  • Any preparation ( or marketed, including FX006), any biologic agent (e.g., rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection; investigational or marketed)
  • IA treatment of the index joint with hyaluronic acid (investigational or marketed) within 6 months of Screening
  • Parenteral or oral corticosteroids (investigational or marketed) within 3 months of Screening
  • Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening
  • Females who are pregnant or nursing or plan to become pregnant during the study; men who plan to conceive during the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    FX006 32 mg

    Single intra-articular (IA) injection of FX006 32 mg

    Drug: FX006 32 mg

  • Active comparator
    TAcs 40 mg

    Single intra-articular (IA) injection of TAcs 40 mg

    Drug: TAcs 40 mg

Interventions

  • Extended-release 32 mg FX006 IA injection

    Also known as: Zilretta

  • Immediate-release 40mg TAcs IA injection

    Also known as: Kenalog®-40 Injection, Triamcinolone Acetonide Crystalline Suspension (TAcs), TCA-IR 40

06

What researchers measure

Primary outcomes

  1. Concentration of Triamcinolone Acetonide (TA) in Blood Plasma

    Characterize the Pharmacokinetic Profile of FX006 and TCA IR \[Time Frame: Day 1 (pre-treatment,1, 2, 3, 4, 5, 6, 8,10, and 12 hrs. post-dose) and Days 2, 3, 5, 8, 15, 22, 29, 57,and 85\] For the PK analysis and individual concentration vs. time plots, a concentration that is BLOQ is assigned a value of zero if it occurs in a profile before the first measurable concentration. If a BLOQ value occurs after a measurable concentration in a profile and is followed by a value above the lower limit of quantification, then the BLOQ is treated as missing data. If a BLOQ value occurs at the end of the collection interval (after the last quantifiable concentration) it is set to zero. If two BLOQ values occur in succession after Cmax, the profile is deemed to have terminated at the first BLOQ value and any subsequent concentrations are set to zero for PK calculations

    Time frame: 12 Weeks

  2. Total Number of Treatment Emergent Adverse Events

    Analyses of adverse events (AE) were performed for events considered treatment-emergent (TE). TE was defined as any AE with onset after administration of the 1st dose of study drug or any event present at baseline but worsened in intensity through the study. Severity was graded by the PI using the Common Terminology Criteria for AEs Version 4.0. Grading went from Grade 1 (Mild) to Grade 5 (Death Related to AE).

    Time frame: 12 Weeks

07

Results

Posted Dec 9, 2019
Limitations and caveats
4 patients with hip as index joint, were excluded from the PK population. 3 patients had incomplete FX006 administration. 1 patient enrolled at 2 different study centers; receiving TAcs and FX006 5 days apart in the same hip with no TEAEs reported.

Participant flow

The recruitment period for this study was from December 2017 to July 2018. The patients were enrolled at medical clinics.

Participant flow — Overall Study
MilestoneFX006 32 mg ShoulderTAcs 40 mg ShoulderFX006 32 mg HipTAcs 40 mg Hip
Started12131515
Completed12131414
Not completed0011
Withdrew: Physician decision0010
Withdrew: Withdrawal by subject0001

Outcome measures

PrimaryConcentration of Triamcinolone Acetonide (TA) in Blood Plasma

Characterize the Pharmacokinetic Profile of FX006 and TCA IR \[Time Frame: Day 1 (pre-treatment,1, 2, 3, 4, 5, 6, 8,10, and 12 hrs. post-dose) and Days 2, 3, 5, 8, 15, 22, 29, 57,and 85\] For the PK analysis and individual concentration vs. time plots, a concentration that is BLOQ is assigned a value of zero if it occurs in a profile before the first measurable concentration. If a BLOQ value occurs after a measurable concentration in a profile and is followed by a value above the lower limit of quantification, then the BLOQ is treated as missing data. If a BLOQ value occurs at the end of the collection interval (after the last quantifiable concentration) it is set to zero. If two BLOQ values occur in succession after Cmax, the profile is deemed to have terminated at the first BLOQ value and any subsequent concentrations are set to zero for PK calculations

Time frame:
12 Weeks
Reported as:
Geometric mean · pg/mL
Concentration of Triamcinolone Acetonide (TA) in Blood Plasma
pg/mLFX006 32 mg ShoulderTAcs 40 mg ShoulderFX006 32 mg HipTAcs 40 mg Hip
Day 1 - Hour 11061.8 (819.95 to 1375.09)1104.1 (578.17 to 2108.52)681.8 (334.47 to 1389.69)3862.3 (2024.11 to 7370.02)
Day 1 - Hour 21117.6 (838.98 to 1488.62)1344.8 (682.40 to 2650.05)752.2 (364.55 to 1551.90)4052.4 (2134.61 to 7693.33)
Day 1 - Hour 31140.0 (849.77 to 1529.44)1501.8 (774.05 to 2913.69)748.0 (349.37 to 1601.44)4519.3 (2286.88 to 8930.88)
Day 1 - Hour 41142.4 (822.55 to 1586.49)1594.1 (856.43 to 2967.05)776.1 (352.73 to 1707.82)4557.8 (2362.49 to 8793.00)
Day 1 - Hour 51093.8 (759.94 to 1574.40)1662.7 (861.73 to 3208.09)792.9 (360.39 to 1744.51)4672.6 (2429.24 to 8987.65)
Day 1 - Hour 61052.8 (729.94 to 1518.37)1689.6 (893.53 to 3194.85)743.5 (331.07 to 1669.73)4469.8 (2393.87 to 8346.03)
Day 1 - Hour 81016.2 (702.66 to 1469.64)1668.3 (887.88 to 3134.86)705.0 (307.07 to 1618.77)4102.3 (2232.93 to 7536.76)
Day 1 - Hour 10951.4 (670.78 to 1349.34)1506.3 (819.27 to 2769.61)698.2 (307.74 to 1583.97)3615.6 (2033.96 to 6427.30)
Day 1 - Hour 12903.8 (637.58 to 1281.10)1531.3 (806.98 to 2905.65)675.1 (296.00 to 1539.62)3276.2 (1858.64 to 5775.00)
Day 2 - Hour 24943.4 (690.74 to 1288.35)1467.0 (884.10 to 2434.35)791.0 (340.46 to 1837.60)3218.8 (1965.24 to 5272.05)
Day - 3903.4 (639.75 to 1275.69)1413.1 (856.25 to 2332.05)682.1 (292.51 to 1590.60)1723.6 (1218.72 to 2437.70)
Day - 5754.6 (536.22 to 1061.93)1038.2 (724.11 to 1488.44)562.4 (242.23 to 1305.93)897.3 (644.77 to 1248.66)
Day - 8678.1 (497.82 to 923.66)857.8 (596.48 to 1233.52)472.3 (202.04 to 1103.90)525.3 (296.03 to 932.01)
Day - 15397.6 (287.43 to 549.88)722.7 (574.45 to 909.25)382.6 (270.89 to 540.52)444.7 (278.24 to 710.85)
Day - 22268.3 (186.53 to 385.82)476.7 (333.94 to 680.44)235.0 (170.80 to 323.29)331.6 (214.93 to 511.48)
Day - 29201.0 (134.57 to 300.21)418.7 (300.39 to 583.66)256.3 (173.31 to 379.15)281.8 (179.32 to 442.91)
Day - 57151.8 (92.60 to 248.73)200 (140.83 to 284.08)225.1 (156.31 to 324.15)133.1 (74.28 to 238.50)
Day - 85100.1 (54.22 to 184.86)131.4 (64.14 to 269.25)112.0 (58.14 to 215.61)92.5 (51.16 to 167.11)
PrimaryTotal Number of Treatment Emergent Adverse Events

Analyses of adverse events (AE) were performed for events considered treatment-emergent (TE). TE was defined as any AE with onset after administration of the 1st dose of study drug or any event present at baseline but worsened in intensity through the study. Severity was graded by the PI using the Common Terminology Criteria for AEs Version 4.0. Grading went from Grade 1 (Mild) to Grade 5 (Death Related to AE).

Time frame:
12 Weeks
Reported as:
Number · Events
Total Number of Treatment Emergent Adverse Events
EventsFX006 32 mg ShoulderTAcs 40 mg ShoulderFX006 32 mg HipTAcs 40 mg Hip
Total Number of Treatment Emergent Adverse Events107817

Adverse events

Collected over Adverse events were collected following IA administration through the final study visit at 12 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FX006 32 mg Shoulder0/12 (0%)0/12 (0%)4/12 (33.3%)
TAcs 40 mg Shoulder0/13 (0%)0/13 (0%)3/13 (23.1%)
FX006 32 mg Hip0/15 (0%)0/15 (0%)4/15 (26.7%)
TAcs 40 mg Hip0/15 (0%)0/15 (0%)7/15 (46.7%)
Most frequent other events
Showing 10 of 32
Most frequent other events
EventFX006 32 mg ShoulderTAcs 40 mg ShoulderFX006 32 mg HipTAcs 40 mg Hip
NasopharyngitisInfections and infestations2/120/130/151/15
ArthralgiaMusculoskeletal and connective tissue disorders0/120/131/152/15
Influenza Like IllnessGeneral disorders1/120/130/150/15
Upper Respiratory Tract InfectionInfections and infestations1/120/131/151/15
Urinary Tract InfectionInfections and infestations1/120/130/150/15
Joint Range of Motion DecreasedMusculoskeletal and connective tissue disorders1/121/130/150/15
Musculoskeletal DiscomfortMusculoskeletal and connective tissue disorders1/120/130/150/15
Pain In ExtremityMusculoskeletal and connective tissue disorders1/120/130/150/15
Respiratory Tract CongestionRespiratory, thoracic and mediastinal disorders1/120/130/150/15
Melanocytic HypoplasiaSkin and subcutaneous tissue disorders1/120/130/150/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)FX006 32 mg ShoulderTAcs 40 mg ShoulderFX006 32 mg HipTAcs 40 mg HipTotal
Mean63.2 ± 11.3961.9 ± 8.1058.1 ± 7.6060.1 ± 7.0960.7 ± 8.53
Sex: Female, Male
Sex: Female, Male(Participants)FX006 32 mg ShoulderTAcs 40 mg ShoulderFX006 32 mg HipTAcs 40 mg HipTotal
Female968528
Male3771027
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FX006 32 mg ShoulderTAcs 40 mg ShoulderFX006 32 mg HipTAcs 40 mg HipTotal
Hispanic or Latino30115
Not Hispanic or Latino913141450
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FX006 32 mg ShoulderTAcs 40 mg ShoulderFX006 32 mg HipTAcs 40 mg HipTotal
American Indian or Alaska Native00011
Asian00101
Native Hawaiian or Other Pacific Islander00101
Black or African American125513
White10118938
More than one race00000
Unknown or Not Reported10001
Region of Enrollment
Region of Enrollment(participants)FX006 32 mg ShoulderTAcs 40 mg ShoulderFX006 32 mg HipTAcs 40 mg HipTotal
United States1213151555
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/mg^2)FX006 32 mg ShoulderTAcs 40 mg ShoulderFX006 32 mg HipTAcs 40 mg HipTotal
Mean28.9 ± 5.9830.7 ± 3.5929.3 ± 3.4931.0 ± 4.4030.01 ± 4.367
08

Study locations

6 sites
  • TriWest Research Associates, LLC
    El Cajon, California 92020, United States
  • Biosolutions Clinical Research Center
    La Mesa, California 91942, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • LA Biomed at Harbor-UCLA Medical Center
    Torrance, California 90509, United States
  • Rochester Clinical Research
    Rochester, New York 14609, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
09

References and documents

Publications

  • Kivitz A, Mehra P, Hanson P, Kwong L, Cinar A, Lufkin J, Kelley S. A Randomized, Open-Label, Single-Dose Study to Assess Safety and Systemic Exposure of Triamcinolone Acetonide Extended-Release in Patients With Hip Osteoarthritis. Rheumatol Ther. 2022 Apr;9(2):679-691. doi: 10.1007/s40744-022-00430-3. Epub 2022 Mar 8. PubMed 35258839 ↗
  • Hanson P, Kivitz A, Mehra P, Kwong L, Cinar A, Lufkin J, Kelley SD. Safety and Systemic Exposure of Triamcinolone Acetonide Following Ultrasound-Guided Intra-Articular Injection of Triamcinolone Extended-Release or Standard Triamcinolone Acetonide in Patients with Shoulder Osteoarthritis: An Open-Label, Randomized Study. Drugs R D. 2021 Sep;21(3):285-293. doi: 10.1007/s40268-021-00348-1. Epub 2021 Aug 4. PubMed 34350546 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Oct 2018, 9 months.

Results were first posted in Dec 2019, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2017
First posted
Dec 22, 2017
StartActual
Dec 18, 2017
Primary completionActual
Oct 9, 2018
CompletionActual
Oct 9, 2018
Results first posted
Dec 9, 2019
Last update
Jan 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03382262
Responsible party
Sponsor
First posted
Dec 22, 2017
Start date
Dec 18, 2017
Primary completion
Oct 9, 2018
Completion
Oct 9, 2018
Results posted
Dec 9, 2019
Last update
Jan 24, 2024

Study contacts

Scott Kelley, MD
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FX006

Start the discussion